Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Merck
Dow
Baxter
Johnson and Johnson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,333,045

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,333,045 protect, and when does it expire?

Patent 6,333,045 protects ZYMAR and is included in one NDA.

Protection for ZYMAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty patent family members in sixteen countries.

Summary for Patent: 6,333,045
Title: Aqueous liquid pharmaceutical composition comprised of gatifloxacin
Abstract:There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (.+-.)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazi nyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.
Inventor(s): Yasueda; Shinichi (Kobe, JP), Inada; Katsuhiro (Kobe, JP)
Assignee: Senju Pharmaceutical Co., Ltd. (Osaka, JP) Kyorin Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:09/529,882
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,333,045
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 6,333,045

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan ZYMAR gatifloxacin SOLUTION/DROPS;OPHTHALMIC 021493-001 Mar 28, 2003 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,333,045

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10/235432Aug 21, 1998
PCT Information
PCT FiledAugust 20, 1999PCT Application Number:PCT/JP99/04483
PCT Publication Date:March 02, 2000PCT Publication Number: WO00/10570

International Family Members for US Patent 6,333,045

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 332692   Start Trial
Australia 5302699   Start Trial
Australia 761040   Start Trial
Brazil 9906735   Start Trial
Brazil PI9906735   Start Trial
Canada 2307632   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
McKinsey
Baxter
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.